Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma

摘要: Little is known about the efficacy of salvage chemotherapy for patients with metastatic, noncutaneous melanoma after failure dacarbazine-based chemotherapy. Because high incidence in Korea, we assessed outcomes paclitaxel/carboplatin (PC) metastatic melanoma. We retrospectively analyzed who received intravenous paclitaxel (175 mg/m) plus carboplatin (area under curve 5) on day 1 a 21-day cycle as at Samsung Medical Center (SMC) between February 2009 and 2012. The overall response rate, survival, progression-free survival were evaluated. Thirty-two median age 54 years (range 24-72 years) PC All had been pretreated three systemic chemotherapies. Of 32 patients, 10 (31.3%) cutaneous melanoma, eight (25%) acral mucosal two (6.3%) ocular In to treatment, seven (21.9%) achieved partial 11 (34.4%) stable disease. was 2.53 months all 4.3 controlled disease (partial disease), 1.37 progressive (P=0.0001). 5.2 months. No significant difference noted (P=0.75). may be reasonable therapeutic option heavily patients. Salvage therapy this combination definite clinically meaningful benefits including those